[White] Announcement of Reappointment of Chairman and Vice Chairman
White Biotech announced on June 9, 2025, that Chairman Li Yili and Vice Chairman Li Yiling have been reappointed to their positions by the board of directors. This personnel change is due to the expiration of their terms, indicating stability in the company's senior management and a continuation of its existing operational strategies.
📋 Article Processing Timeline
- 📰 Published: June 9, 2026 at 09:00
- 🔍 Collected: June 10, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: June 12, 2026 at 17:53 (57h 53m after Collected)
1. Date of Board Resolution or Change: 115/06/09
2. Personnel Category (Please enter Chairman or General Manager): Chairman and Vice Chairman
3. Names of Previous Incumbents:
(1) Chairman: Li Yili
(2) Vice Chairman: Li Yiling
4. Brief Resumes of Previous Incumbents:
(1) Chairman: Li Yili, Resume: Chairman of White Biotechnology New Drug (Stock) Company
(2) Vice Chairman: Li Yiling, Resume: Vice Chairman and General Manager of White Biotechnology New Drug (Stock) Company
5. Names of New Incumbents:
(1) Chairman: Li Yili
(2) Vice Chairman: Li Yiling
6. Brief Resumes of New Incumbents:
(1) Chairman: Li Yili, Resume: Chairman of White Biotechnology New Drug (Stock) Company
(2) Vice Chairman: Li Yiling, Resume: Vice Chairman and General Manager of White Biotechnology New Drug (Stock) Company
7. Change Details (Please enter 'Resignation', 'Dismissal', 'Term Expiration', 'Job Adjustment', 'Redundancy', 'Retirement', 'Death', or 'New Appointment'): Term Expiration
8. Reason for Change: Term expiration, re-elected by the company's board of directors on June 9, 2025.
9. Effective Date of New Appointment: 115/06/09
10. Other Matters to be Noted (If the subject of the event or resolution is a publicly issued company or above, and this major information also meets the criteria of Article 7, Paragraph 6 of the Regulations Governing the Application of the Securities Transaction Act regarding matters that have a significant impact on shareholder equity or securities prices):
None.
Keywords: Major Information
2. Personnel Category (Please enter Chairman or General Manager): Chairman and Vice Chairman
3. Names of Previous Incumbents:
(1) Chairman: Li Yili
(2) Vice Chairman: Li Yiling
4. Brief Resumes of Previous Incumbents:
(1) Chairman: Li Yili, Resume: Chairman of White Biotechnology New Drug (Stock) Company
(2) Vice Chairman: Li Yiling, Resume: Vice Chairman and General Manager of White Biotechnology New Drug (Stock) Company
5. Names of New Incumbents:
(1) Chairman: Li Yili
(2) Vice Chairman: Li Yiling
6. Brief Resumes of New Incumbents:
(1) Chairman: Li Yili, Resume: Chairman of White Biotechnology New Drug (Stock) Company
(2) Vice Chairman: Li Yiling, Resume: Vice Chairman and General Manager of White Biotechnology New Drug (Stock) Company
7. Change Details (Please enter 'Resignation', 'Dismissal', 'Term Expiration', 'Job Adjustment', 'Redundancy', 'Retirement', 'Death', or 'New Appointment'): Term Expiration
8. Reason for Change: Term expiration, re-elected by the company's board of directors on June 9, 2025.
9. Effective Date of New Appointment: 115/06/09
10. Other Matters to be Noted (If the subject of the event or resolution is a publicly issued company or above, and this major information also meets the criteria of Article 7, Paragraph 6 of the Regulations Governing the Application of the Securities Transaction Act regarding matters that have a significant impact on shareholder equity or securities prices):
None.
Keywords: Major Information
FAQ
Is White Biotech's management team stable?
Yes, the reappointment of the Chairman and Vice Chairman confirms the stability of the management team, which is a positive factor for business continuity.
How will this personnel change affect the company's future?
The continuation of the current management suggests that existing R&D strategies and business plans will be maintained, leading to expectations of stable growth.
What kind of business does White Biotech engage in?
White Biotech is primarily a biotechnology company focused on the research and development of new drugs.
What is the significance of this news for investors?
Management stability enhances the company's credibility and can serve as a reassuring factor for long-term investment decisions.
What should investors look out for regarding White Biotech's future developments?
Progress in the R&D pipeline and announcements of new clinical trials are likely points of interest.